Understanding Contemporary Use of Thiazolidinediones An Analysis From the Diabetes Collaborative Registry
Understanding Contemporary Use of Thiazolidinediones An Analysis From the Diabetes Collaborative Registry
复制标题
DOI：
10.1161/circheartfailure.118.005855
复制
发表时间：
2019-06-01
影响因子：
9.7
通讯作者：
Kosiborod, Mikhail
中科院分区：
文献类型：
--
作者：
Arnold, Suzanne V.;Inzucchi, Silvio E.;Kosiborod, Mikhail
背景资料：噻唑烷二酮类（罗格列酮、吡格列酮）是用于2型糖尿病的口服胰岛素增敏药物，可降低血糖，低血糖风险最小，对动脉粥样硬化有潜在益处。然而，噻唑烷二酮类药物可引起液体潴留，从而增加心力衰竭的风险，心力衰竭是2型糖尿病的常见并发症。方法和结果：数据来自糖尿病协作登记处，这是一个美国2型糖尿病患者的门诊登记处，目前包括203个心脏病学，内分泌学和初级保健实践和3074个提供者。在糖尿病协作登记处登记的424061名患有2型糖尿病并服用≥ 1种降糖药物的美国成人中，35018名患者（8.3%）服用噻唑烷二酮，该药物随时间推移保持稳定。接受噻唑烷二酮类药物治疗的患者年龄较大（平均年龄69.2 ± 10.7岁），61.9%患有冠心病，17.2%患有3级肥胖。总体而言，40.3%接受噻唑烷二酮治疗的患者临床诊断为心力衰竭（23.7%），射血分数为
Background: Thiazolidinediones (rosiglitazone, pioglitazone) are oral insulin-sensitizing medications used in type 2 diabetes mellitus that reduce glucose with minimal risk of hypoglycemia and potential benefits on atherosclerosis. However, thiazolidinediones can cause fluid retention thereby increasing the risk of heart failure-a common complication of type 2 diabetes mellitus. Methods and Results: Data were analyzed from the Diabetes Collaborative Registry, a US outpatient registry of patients with type 2 diabetes mellitus that currently encompasses 203 cardiology, endocrinology, and primary care practices and 3074 providers. Among 424 061 US adults enrolled in Diabetes Collaborative Registry who had type 2 diabetes mellitus and were taking >= 1 glucose-lowering medication, 35 018 patients (8.3%) were on a thiazolidinedione, which has remained stable over time. Patients on thiazolidinediones tended to be old (mean age, 69.2 +/- 10.7 years), 61.9% had coronary disease, and 17.2% had class 3 obesity. In total, 40.3% of patients on a thiazolidinedione had either a clinical diagnosis of heart failure (23.7%), had an ejection fraction of